{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:04:08Z","timestamp":1773680648989,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived lymphoma entity accounting for \u22485% of all Hodgkin lymphoma (HL) cases. In recent decades, patients with newly diagnosed NLPHL have usually been treated very similarly to classical HL (cHL). The 10-year overall survival rates with HL-directed approaches are in excess of 90%. However, pathological and clinical characteristics of NLPHL resemble indolent B-cell non-Hodgkin lymphoma (B-NHL) in some aspects. Thus, nodular lymphocyte-predominant B-cell lymphoma has been proposed as an alternative name, and the use of B-NHL-directed treatment strategies has become more common in NLPHL despite limited data. Given the often indolent clinical course of NLPHL, even in the case of relapse, the majority of patients with disease recurrence do not require high-dose chemotherapy and autologous stem cell transplantation but are treated sufficiently with low-intensity approaches such as single-agent anti-CD20 antibody treatment. The establishment of novel prognostic scores for NLPHL patients may optimize risk group and treatment allocation in newly diagnosed and relapsed disease.<\/jats:p>","DOI":"10.3390\/cancers15133310","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T03:14:56Z","timestamp":1687749296000},"page":"3310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?"],"prefix":"10.3390","volume":"15","author":[{"given":"Dennis A.","family":"Eichenauer","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, D-50937 Cologne, Germany"},{"name":"German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, D-50937 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-3272","authenticated-orcid":false,"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, D-50937 Cologne, Germany"},{"name":"German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, D-50937 Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/asheducation-2017.1.324","article-title":"Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management","volume":"2017","author":"Eichenauer","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Younes, S., Rojansky, R.B., Menke, J.R., Gratzinger, D., and Natkunam, Y. (2021). Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics. Cancers, 13.","DOI":"10.3390\/cancers13123021"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjh.12997","article-title":"Histopathological Features and Their Prognostic Impact in Nodular Lymphocyte-Predominant Hodgkin Lymphoma\u2014A Matched Pair Analysis from the German Hodgkin Study Group (GHSG)","volume":"167","author":"Hartmann","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PAS.0000000000000107","article-title":"EBV May Be Expressed in the LP Cells of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults","volume":"38","author":"Huppmann","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The Prognostic Impact of Variant Histology in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.18376","article-title":"Tumour Cell Characteristics and Microenvironment Composition Correspond to Clinical Presentation in Newly Diagnosed Nodular Lymphocyte-predominant Hodgkin Lymphoma","volume":"199","author":"Hartmann","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ajh.25607","article-title":"The Time to Relapse Correlates with the Histopathological Growth Pattern in Nodular Lymphocyte Predominant Hodgkin Lymphoma","volume":"94","author":"Hartmann","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pathol.2019.10.003","article-title":"Nodular Lymphocyte Predominant Hodgkin Lymphoma: Pathology, Clinical Course and Relation to T-Cell\/Histiocyte Rich Large B-Cell Lymphoma","volume":"52","author":"Hartmann","year":"2020","journal-title":"Pathology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-Predominant and Classical Hodgkin\u2019s Lymphoma: A Comprehensive Analysis from the German Hodgkin Study Group","volume":"26","author":"Nogova","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.16290","article-title":"Primary Therapy and Survival among Patients with Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Population-based Analysis in the Netherlands, 1993\u20132016","volume":"189","author":"Posthuma","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, Lymphocyte-Predominant Hodgkin Lymphoma: A Long-Term Study and Analysis of Transformation to Diffuse Large B-Cell Lymphoma in a Cohort of 164 Patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin\u2019s Lymphoma","volume":"28","author":"Connors","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended Field Radiotherapy, Combined Modality Treatment or Involved Field Radiotherapy for Patients with Stage IA Lymphocyte-Predominant Hodgkin\u2019s Lymphoma: A Retrospective Analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogova","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-Stage, Lymphocyte-Predominant Hodgkin\u2019s Lymphoma: Patient Outcomes from a Large, Single-Institution Series with Long Follow-Up","volume":"28","author":"Chen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children\u2019s Oncology Group","volume":"34","author":"Appel","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.18169","article-title":"Management of Children and Adults with All Stages of Nodular Lymphocyte Predominant Hodgkin Lymphoma\u2014All StAGEs: A Consensus-based Position Paper from the Hodgkin Lymphoma Subgroup of the UK National Cancer Research Institute","volume":"197","author":"Shankar","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0035-1559664","article-title":"Pediatric Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group","volume":"227","author":"Lange","year":"2015","journal-title":"Klin. P\u00e4diatrie"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Multi-Institutional Study of Adult Patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating Limited-Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Similarly to Classical Hodgkin Lymphoma with ABVD May Improve Outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gotti, M., Sciarra, R., Pulsoni, A., Merli, F., Luminari, S., Zerbi, C., Trentin, L., Re, A., Rusconi, C., and Viviani, S. (2023). Role of Rituximab Addition to First-Line Chemotherapy Regimens in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. HemaSphere, 7.","DOI":"10.1097\/HS9.0000000000000837"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Compared with Classical Hodgkin Lymphoma: A Matched Pair Outcome Analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Long-Term Follow-up of a Phase 2 Study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vuolio, T., Kuittinen, O., V\u00e4yrynen, J.P., Teppo, H., Prusila, R.E.I., R\u00e4met, M., Kuitunen, H., Paloneva, T., and Kuusisto, M.E.L. (2023). R-bendamustine in the Treatment of Nodular Lymphocyte Predominant Hodgkin Lymphoma\u2014An Extended Follow-up. Br. J. Haematol., online ahead of print.","DOI":"10.1111\/bjh.18896"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Eichenauer, D.A., B\u00fchnen, I., Baues, C., Kobe, C., Kaul, H., Greil, R., Moccia, A.A., Zijlstra, J.M., Hertenstein, B., and Topp, M.S. (2023). Interim PET-Guided Treatment for Early-Stage NLPHL: A Subgroup Analysis of the Randomized GHSG HD16 and HD17 Studies. Blood J.","DOI":"10.1182\/blood.2023019939"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2021.02.018","article-title":"PET-2-Guided Escalated BEACOPP for Advanced Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Subgroup Analysis of the Randomized German Hodgkin Study Group HD18 Study","volume":"32","author":"Eichenauer","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Pugliese, N., Picardi, M., Della Pepa, R., Giordano, C., Muriano, F., Leone, A., Delle Cave, G., D\u2019Ambrosio, A., Marafioti, V., and Rascato, M.G. (2021). Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. Cancers, 13.","DOI":"10.3390\/cancers13081760"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-Bendamustine in the Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1080\/10428194.2022.2053533","article-title":"Practice Patterns for the Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An International Survey by the Global NLPHL One Working Group (GLOW)","volume":"63","author":"Lo","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment Outcome after Low Intensity Chemotherapy [CVP] in Children and Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin\u2019s Lymphoma\u2014An Anglo-French Collaborative Report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14567","article-title":"Nodular Lymphocyte Predominant Hodgkin Lymphoma in Sweden between 2000 and 2014: An Analysis of the Swedish Lymphoma Registry","volume":"177","author":"Molin","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in Relapsed Lymphocyte-Predominant Hodgkin Lymphoma: Long-Term Results of a Phase 2 Trial by the German Hodgkin Lymphoma Study Group (GHSG)","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2015.321","article-title":"Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Results of a Phase II Study from the German Hodgkin Study Group","volume":"30","author":"Eichenauer","year":"2016","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hon.2986","article-title":"Phase II Study of Fixed-duration Single-agent Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group","volume":"40","author":"Eichenauer","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2018-02-836437","article-title":"Relapsed and Refractory Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group","volume":"132","author":"Eichenauer","year":"2018","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.17281","article-title":"Outcome of Relapsed and Refractory Nodular Lymphocyte-predominant Hodgkin Lymphoma: A North American Analysis","volume":"192","author":"Strati","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.24927","article-title":"High Dose Chemotherapy and Autologous Stem Cell Transplantation in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation-Lymphoma Working Party","volume":"93","author":"Akhtar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2015-08-665505","article-title":"Large B-Cell Transformation in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: 40-Year Experience from a Single Institution","volume":"127","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23989","article-title":"Incidence, Management, and Outcome of High-Grade Transformation of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Long-Term Outcomes from a 30-Year Experience","volume":"90","author":"Eyre","year":"2015","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:59:19Z","timestamp":1760126359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":48,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133310"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133310","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]}}}